These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10850293)

  • 21. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
    Wilkinson S; Chodak G
    J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
    Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL
    Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide.
    Hinkle GH; Burgers JK; Olsen JO; Williams BS; Lamatrice RA; Barth RF; Rogers B; Maguire RT
    J Nucl Med; 1998 Apr; 39(4):650-2. PubMed ID: 9544673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
    Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
    Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
    J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
    Rosenthal SA; Haseman MK; Polascik TJ
    Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.
    Elgamal AA; Troychak MJ; Murphy GP
    Prostate; 1998 Dec; 37(4):261-9. PubMed ID: 9831223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indium-111 capromab pendetide in the management of recurrent prostate cancer.
    Manyak MJ
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):175-81. PubMed ID: 18279057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
    Mouraviev V; Madden JF; Broadwater G; Mayes JM; Burchette JL; Schneider F; Smith J; Tsivian M; Wong T; Polascik TJ
    J Urol; 2009 Sep; 182(3):938-47. PubMed ID: 19616259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
    Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
    Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
    Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
    Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy.
    Murphy GP; Elgamal AA; Troychak MJ; Kenny GM
    Prostate; 2000 Mar; 42(4):315-7. PubMed ID: 10679761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible false-positive metastatic prostate cancer on an In-111 capromab pendetide scan as a result of a pelvic kidney.
    Valliappan S; Joyce JM; Myers DT
    Clin Nucl Med; 1999 Dec; 24(12):984-5. PubMed ID: 10595486
    [No Abstract]   [Full Text] [Related]  

  • 37. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.
    Petronis JD; Regan F; Lin K
    Clin Nucl Med; 1998 Oct; 23(10):672-7. PubMed ID: 9790041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.